For research use only
| Cat No. | ABC-TC0147 |
| Product Type | Mouse Lung Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Mouse |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Product Code | CMT64-61, CMT64 61, CMT 64/61 |
Mouse C57BL/1CRF lung carcinoma. Derived from an alveologenic lung carcinoma from a C57BL/1CRF mouse.
The CMT64/61 cell line is a murine lung carcinoma subline derived from an alveologenic tumor in a C57BL/1CRF mouse. These cells exhibit a characteristic cobblestone-like epithelial morphology and adherent growth. Upon TGF-β stimulation, CMT64/61 cells undergo epithelial-to-mesenchymal transition, characterized by reduced E-cadherin and elevated fibronectin expression. These cells carry an activating Kras mutation while retaining wild-type p53. CMT64/61 cells are known for forming both primary lung tumors and metastatic nodules in syngeneic mouse models, making them a relevant platform for studying lung cancer progression and EMT dynamics. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from mycoplasma, fungi, yeast, and bacteria.
| Product Code | CMT64-61, CMT64 61, CMT 64/61 |
| Species | Mouse |
| Cat.No | ABC-TC0147 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Lung Cancer Cell Lines |
CMT64/61 is widely used for preclinical cancer research, especially in models of Kras-driven lung adenocarcinoma. Its tumorigenic and metastatic behavior in immunocompetent mice supports research on tumor progression, epithelial–mesenchymal transition (EMT), and therapeutic resistance. It is also suitable for testing oncolytic viruses, immune checkpoint inhibitors, and other immunotherapies. Researchers frequently use this line to explore TGF-β–induced EMT, given its clear morphological and gene expression changes. With its stable growth and metastatic profile, CMT64/61 provides a robust platform for anti-cancer drug screening, mechanistic studies, and metastasis-targeting strategies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
